These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 24412300

  • 1. Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella.
    Streng A, Liese JG.
    Vaccine; 2014 Feb 12; 32(8):897-900. PubMed ID: 24412300
    [Abstract] [Full Text] [Related]

  • 2. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M, Broder KR, Temte JL, Snider DE, Seward JF, Centers for Disease Control and Prevention (CDC).
    MMWR Recomm Rep; 2010 May 07; 59(RR-3):1-12. PubMed ID: 20448530
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.
    Pediatr Infect Dis J; 2008 Aug 07; 27(8):724-30. PubMed ID: 18600190
    [Abstract] [Full Text] [Related]

  • 4. Influences on immunization rates: Vaccination coverage of mumps, measles, rubella and varicella before and after the STIKO intervention 2011 - A retrospective study.
    Sanftenberg L, Schrörs HJ, Schelling J.
    Vaccine; 2016 Jul 25; 34(34):3938-41. PubMed ID: 27318420
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
    Lalwani S, Chatterjee S, Balasubramanian S, Bavdekar A, Mehta S, Datta S, Povey M, Henry O.
    BMJ Open; 2015 Sep 11; 5(9):e007202. PubMed ID: 26362659
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P, Lim FS, Han HH, Willems P.
    Infection; 2007 Oct 11; 35(5):326-33. PubMed ID: 17710370
    [Abstract] [Full Text] [Related]

  • 7. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.
    Schink T, Holstiege J, Kowalzik F, Zepp F, Garbe E.
    Vaccine; 2014 Feb 03; 32(6):645-50. PubMed ID: 24374498
    [Abstract] [Full Text] [Related]

  • 8. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ, Consistency Lot Study Group for ProQuad.
    Pediatr Infect Dis J; 2006 Jul 03; 25(7):615-22. PubMed ID: 16804432
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
    Macartney K, Gidding HF, Trinh L, Wang H, Dey A, Hull B, Orr K, McRae J, Richmond P, Gold M, Crawford N, Kynaston JA, McIntyre P, Wood N, Paediatric Active Enhanced Disease Surveillance Network.
    JAMA Pediatr; 2017 Oct 01; 171(10):992-998. PubMed ID: 28806450
    [Abstract] [Full Text] [Related]

  • 10. Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella (MMRV-Priorix-Tetra™) Compared to Separate MMR + V Vaccination.
    Bauchau V, Van Holle L, Cohen C.
    Drug Saf; 2015 Nov 01; 38(11):1095-102. PubMed ID: 26251259
    [Abstract] [Full Text] [Related]

  • 11. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
    Casabona G, Berton O, Singh T, Knuf M, Bonanni P.
    Expert Rev Vaccines; 2023 Nov 01; 22(1):764-776. PubMed ID: 37642012
    [Abstract] [Full Text] [Related]

  • 12. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, Douha M, Willems P.
    Eur J Pediatr; 2012 Mar 01; 171(3):463-70. PubMed ID: 21935584
    [Abstract] [Full Text] [Related]

  • 13. Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children.
    Committee on Infectious Diseases.
    Pediatrics; 2011 Sep 01; 128(3):630-2. PubMed ID: 21873692
    [Abstract] [Full Text] [Related]

  • 14. Association of the use of MMRV in infants by pediatric infectious disease specialists with that of other affiliated providers.
    Ackerson BK, Li BH, Sy LS, Cheetham TC, Jacobsen SJ.
    Vaccine; 2014 Apr 01; 32(16):1863-8. PubMed ID: 24508041
    [Abstract] [Full Text] [Related]

  • 15. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR, Black S, Kuter BJ.
    J Infect Dis; 2008 Mar 01; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH, Hirai HW, Tsoi KK.
    Expert Rev Vaccines; 2015 Mar 01; 14(8):1149-57. PubMed ID: 26081133
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, Descamps D, Willems P.
    Pediatr Infect Dis J; 2006 Jan 01; 25(1):12-8. PubMed ID: 16395096
    [Abstract] [Full Text] [Related]

  • 18. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.
    Prymula R, Bergsaker MR, Esposito S, Gothefors L, Man S, Snegova N, Štefkovičova M, Usonis V, Wysocki J, Douha M, Vassilev V, Nicholson O, Innis BL, Willems P.
    Lancet; 2014 Apr 12; 383(9925):1313-1324. PubMed ID: 24485548
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T, Baer M, Willems P.
    Pediatr Infect Dis J; 2007 Feb 12; 26(2):153-8. PubMed ID: 17259879
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P.
    Vaccine; 2009 Jan 14; 27(3):446-53. PubMed ID: 19007835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.